Pfizer Pursuing Innovation via New Biotherapeutics and Bioinnovation Center
November 7, 2007--Corey Goodman, co-founder of biopharmaceutical companies Renovis and Exelixis, has made the leap from biotech to big pharma, having recently taken the helm of Pfizer’s new Biotherapeutics and Bioinnovation Center. Threatened by generic competition (half a dozen of Pfizer's blockbuster drugs have either recently gone off patent or soon will), Goodman’s South San Francisco center is under pressure to form collaborations with biotech companies that will bear new drugs to bolster Pfizer’s pipeline. Goodman hopes to create an independent, entrepreneurial science outfit that will help Pfizer build a product line of biologic drugs. San Francisco Chronicle